Please wait...
About This Project
OncoSynergy, Inc.
The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
Recent Lab Notes From This Project
Browse Other Projects on Experiment
Related Projects
A Bird's-eye View of Frog Habitats: Using a Drone to Survey Wetlands
I study vulnerable frog species that inhabit human-constructed wetlands in the Grand River Grasslands of...
Hot Metal Switch: Synthetic In Vitro Gene Circuit for the Detection of Metal Ions
Drinking water contaminated by metals, most notably lead, poses health risks to children and adults alike...
Performance-enhancing substances: How do male black widows use chemical cues to gain a competitive advantage?
For a male black widow spider, life is a series of deadly challenges. He must first make a dangerous...
